Literature DB >> 3169017

Interaction of heparin and antithrombin III. The role of O-sulfate groups.

M Petitou1, J C Lormeau, J Choay.   

Abstract

A synthetic pentasaccharide corresponding to the sequence involved in heparin for binding and activation of antithrombin III contains eight sulfate groups. The role of some of them in the interaction with the protein has been demonstrated through the study of fragments obtained from heparin. An approach based on the total chemical synthesis of heparin fragments allows us to provide new information on the O-sulfate groups borne by the iduronic acid and the glucosamine units that constitute the reducing-end disaccharide of the above pentasaccharide sequence. Although not strictly necessary for a weak interaction to take place, these two sulfates co-operate to express maximal activity. This suggests that they belong to a secondary sub-region of interaction with antithrombin III, the primary one being accounted for by other critical parts of the structure and particularly the trisaccharide sequence placed at the non-reducing end of the pentasaccharide.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3169017     DOI: 10.1111/j.1432-1033.1988.tb14324.x

Source DB:  PubMed          Journal:  Eur J Biochem        ISSN: 0014-2956


  11 in total

1.  Low anticoagulant heparin disrupts Plasmodium falciparum rosettes in fresh clinical isolates.

Authors:  Anna M Leitgeb; Karin Blomqvist; Fidelis Cho-Ngwa; Moses Samje; Peter Nde; Vincent Titanji; Mats Wahlgren
Journal:  Am J Trop Med Hyg       Date:  2011-03       Impact factor: 2.345

2.  A unique heparin-binding domain in the envelope protein of the neuropathogenic PVC-211 murine leukemia virus may contribute to its brain capillary endothelial cell tropism.

Authors:  A Jinno-Oue; M Oue; S K Ruscetti
Journal:  J Virol       Date:  2001-12       Impact factor: 5.103

3.  Recognition and Conformational Properties of an Alternative Antithrombin Binding Sequence Obtained by Chemoenzymatic Synthesis.

Authors:  Eduardo Stancanelli; Stefano Elli; Po-Hung Hsieh; Jian Liu; Marco Guerrini
Journal:  Chembiochem       Date:  2018-03-24       Impact factor: 3.164

Review 4.  Glycosaminoglycans and the regulation of blood coagulation.

Authors:  M C Bourin; U Lindahl
Journal:  Biochem J       Date:  1993-01-15       Impact factor: 3.857

5.  Conformation of heparin pentasaccharide bound to antithrombin III.

Authors:  M Hricovíni; M Guerrini; A Bisio; G Torri; M Petitou; B Casu
Journal:  Biochem J       Date:  2001-10-15       Impact factor: 3.857

6.  Heparan sulfate phage display antibodies identify distinct epitopes with complex binding characteristics: insights into protein binding specificities.

Authors:  Sophie M Thompson; David G Fernig; Edwin C Jesudason; Paul D Losty; Els M A van de Westerlo; Toin H van Kuppevelt; Jeremy E Turnbull
Journal:  J Biol Chem       Date:  2009-12-18       Impact factor: 5.157

Review 7.  Structure-based design of decoy chemokines as a way to explore the pharmacological potential of glycosaminoglycans.

Authors:  Tiziana Adage; Anna-Maria Piccinini; Angelika Falsone; Martin Trinker; James Robinson; Bernd Gesslbauer; Andreas J Kungl
Journal:  Br J Pharmacol       Date:  2012-11       Impact factor: 8.739

8.  Purification and characterization of serine proteases that exhibit caspase-like activity and are associated with programmed cell death in Avena sativa.

Authors:  Warren C Coffeen; Thomas J Wolpert
Journal:  Plant Cell       Date:  2004-03-12       Impact factor: 11.277

Review 9.  Pharmacotherapeutic aspects of unfractionated and low molecular weight heparins.

Authors:  M Verstraete
Journal:  Drugs       Date:  1990-10       Impact factor: 9.546

10.  Thrombospondin related anonymous protein (TRAP) of Plasmodium falciparum binds specifically to sulfated glycoconjugates and to HepG2 hepatoma cells suggesting a role for this molecule in sporozoite invasion of hepatocytes.

Authors:  H M Müller; I Reckmann; M R Hollingdale; H Bujard; K J Robson; A Crisanti
Journal:  EMBO J       Date:  1993-07       Impact factor: 11.598

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.